NCT06333249View on ClinicalTrials.gov

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

April 11, 2023

Study Completion Date

February 28, 2027

Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIOLOGICAL

rAAV2tYF-GRK1-RPGR

Adeno-associated virus vector expressing a human RPGR gene

Trial Locations (6)

32209

University of Florida, Jacksonville

44195

Cleveland Clinic, Cleveland

45242

Cincinnati Eye Institute, Cincinnati

75231

Retina Foundation of the Southwest, Dallas

97239

Casey Eye Institute, Portland

02115

Boston Children's Hosptial, Boston

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY